Startup Scouting for Corporations
|
See RNAimmune's full profile BOOK A DEMO |
| Headquarters United States |
Founded Year 2021 |
Total Funding
$12.4M |
Employees
1 - 10 |
Status Active |
About RNAimmuneWe are able to deliver a wider variety of mrnas with enhanced intracellular expression. |
HeadquartersUnited States |
General Information on RNAimmune
| Brand name | RNAimmune |
| Company name | RNAimmune Inc.RN |
| Website | https://www.rnaimmune.com/ |
| Founded year | 2021 |
| Employees | 1 - 10 |
| Contact | [email protected] |
|
Find startup solutions in your specific business context The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
|
BOOK A DEMO |
Recent News and Activity about RNAimmune |
|
Daily Record
•
30.03.2022
RNAimmune secures $27M in Series A financingRNAimmune Inc., a biopharmaceutical company in Gaithersburg specializing in discovery and development of mRNA-based therapeutics and vaccines, announced Wednesday it has secured $27 million in a Series A round of financing. The company intends to use the funding to accelerate its research and development of mRNA vaccine and drug discovery focused on infectious disease, cancer, and rare diseases. The round was led by existing shareholders of ... 
|
|
Dagens Industri
•
30.03.2022
EQS-News: RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and VaccinesRNAimmu... |
|
PR Newswire
•
30.03.2022
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and VaccinesGAITHERSBURG, Md., March 30, 2022/ PRNewswire/-- RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US $27 million Series A round of f 
|
|
Menafn.com
•
30.03.2022
RNAimmune Secures $27 Million Series A Round of Financing fo...| MENAFN.COMdiscovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A round of financing. The Company intends to use the funding to accelerate its research and development of mRNA vaccine and drug discovery focused on infectious disease, cancer, and rare diseases. The round was led by existing shareholders of RNAimmune, including Sirnaomics Ltd. (' Sirnaomics ', stock code: ... |
|
usalifesciences.com
•
30.03.2022
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines GAITHERSBURG, Md.Since its establishment in March 2020, RNAimmune has built up its mRNA vaccine and drug discovery and development platform to tackle high unmet medical needs in infectious diseases, cancer and rare diseases. The Company submitted the pre-IND meeting package for its lead candidate, RIM730, an mRNA vaccine for COVID-19 with the U.S. Food and Drug Administration (FDA) in October 2021 and received the green light in January 2022. The Company ... |
|
Bioworld
•
14.12.2021
Rnaimmune measuring its COVID-19 vaccine candidate’s mettle against OmicronRnaimmune Inc., which in April raised a $10 million seed round to support its discovery and development of RNAi therapies, said it is now studying the neutralizing effects of its mRNA-based COVID-19 vaccine candidate on the Omicron variant. “Before Omicron appeared, studies demonstrated that our COVID-19 vaccine showed neutralization against all strains,” Shen Dong, CEO of Rnaimmune, told BioWorld. 
|
Footer
About INNOSPOT
